Breast cancer pill backed by study

Taking the breast cancer pill Femara can significantly reduce the chances that a woman’s cancer will return, even long after she has stopped taking the estrogen blocker tamoxifen, researchers said in Chicago.

They said post-menopausal women who took Femara from one to seven years after finishing a five-year regimen of tamoxifen reduced by 63% the risk the cancer would come back. The study results were published in the Journal of Clinical Oncology.